Drug intelligence / Profile preview

GT-211

Development stage: Phase 2
Lead developer: GTree Pharmaceuticals
Modality: Peptides
Administration: Intravenous, Intramuscular

Overview

GT-211 is a synthetic peptide formulation of thymosin beta 4 (Tβ4) currently under development by HLB Therapeutics (formerly GtreeBNT) for the treatment of Duchenne muscular dystrophy (DMD). Thymosin beta 4 is a naturally occurring 43-amino acid protein that regulates actin polymerization and exhibits potent anti-inflammatory, anti-fibrotic, and regenerative properties. In DMD models, GT-211 aims to mitigate muscle wasting by promoting the migration and differentiation of muscle progenitor cells, reducing the replacement of muscle tissue with fibrous scars, and protecting cardiac muscle from damage. The U.S. FDA granted Orphan Drug Designation to GT-211 for the treatment of DMD in 2018.

Other names: Thymosin beta 4

Targets

HTR3A (5-hydroxytryptamine receptor 3A)Acetylcholinesterase

Beyond the preview

Go deeper on GT-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT-211.

Explore the full profile